Medication info

All-Duo Tablet 5/20 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletAmlodipine Maleate›6.42mg / 1 tablet
Manufacturer / importer
Samchundang Pharm. Co., Ltd.
Appearance
White, round film-coated tablet
Packaging
28 tablets/((14 tablets/Alu-Alu)x2)
Approval status
Approval withdrawn

MFDS item code 201405460 · Approved 2014.11.24

This product's status changed to Approval withdrawn on 2024.03.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled by monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended that the tablet be taken at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be titrated using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows: - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medicine must not be administered to patients with severe hepatic impairment. (See Precautions for Use, 2. Patients Who Must Not Receive This Medicine.) ○ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
Child dose
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Samchundang Pharm. Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled by monotherapy

  • Essential hypertension
View approved original text

This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled with amlodipine or olmesartan medoxomil monotherapy. It effectively lowers blood pressure to reduce the risk of cardiovascular disease and aids in stable blood pressure management. It contributes to improving health by adjusting appropriately to the patient's blood pressure condition.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended that the tablet be taken at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be titrated using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows: - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medicine must not be administered to patients with severe hepatic impairment. (See Precautions for Use, 2. Patients Who Must Not Receive This Medicine.) ○ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This drug can cause serious harm or death to the fetus or newborn if taken during the second or third trimester of pregnancy; therefore, it must be discontinued immediately if pregnancy is confirmed. Do not take this medication if you are allergic to the active ingredients or similar drugs, are pregnant or breastfeeding, have severe liver impairment, or have certain heart diseases. Patients who are depleted of fluid or salt should be monitored closely as this medication can cause significant drops in blood pressure initially. Rare instances of rapid vascular expansion leading to severe drops in blood pressure have been reported, particularly caution is advised for patients with specific heart diseases. Patients with heart failure or impaired kidney function may experience changes in kidney function when taking this medication, so caution is required. Side effects such as dizziness, headache, hypotension, edema, and indigestion may occur during treatment; if you experience any unusual symptoms, consult your physician. The amlodipine component may increase blood pressure-lowering effects when taken with grapefruit juice, so it is advisable to avoid grapefruit juice. If you are pregnant, using this medication may pose a risk to the fetus; therefore, it is necessary to consult a doctor if you are planning to become pregnant or are already pregnant. Breastfeeding mothers should consult their doctor about the possibility of this drug passing into breast milk, considering stopping breastfeeding or discontinuing the drug. The drug is not recommended for children under 18 years of age as safety and efficacy have not been established. Elderly patients should use caution as reduced kidney and liver function may lead to increased serum concentrations of the drug; starting at a low dose is advisable. In cases of overdose, severe hypotension and vascular expansion may occur, requiring immediate medical assistance, and continuous monitoring of heart and respiratory function is necessary. Store this medication in a sealed container away from direct sunlight and moisture, and do not transfer it to another container.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • sensory deficits
  • syncope
Show 79 more
  • vertigo
  • palpitations
  • rapid heartbeat
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • low back pain
  • polyuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • dependent edema
  • fatigue
  • weakness
  • facial edema
  • decreased blood potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyltransferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • exacerbation of cerebral infarction
  • gum bleeding
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • diplopia
  • insomnia
  • weakness
  • vascular edema
  • chronic malabsorption syndrome
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • vascular edema
  • rhabdomyolysis
  • hematuria
  • hyperglycemia
  • hypertriglyceridemia
  • influenza-like symptoms
  • pharyngitis
  • rhinitis
  • sinusitis
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • jaundice
  • elevated liver enzymes
  • hypotension
  • tachycardia
  • bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

White, round film-coated tablet

Package unit

28 tablets/((14 tablets/Alu-Alu)x2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.